BTLA and neoplasm: This mesenchymal tumor phenotype is also associated with an increase in expression of immune checkpoint molecules, comprising B7 Homolog 3 (B7-H3), B and T lymphocyte attenuator (BTLA), CTLA-4, PD-1, PD-L1/2, and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), within the inflammatory TME [321].